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Abstract
Introduction: Both cardiovascular disease and osteoporosis are important causes of morbidity and mortality in the
elderly. The co-occurrence of cardiovascular disease and osteoporosis prompted us to review the evidence of an
association between cardiovascular (CV) disease and osteoporosis and potential shared common
pathophysiological mechanisms.
Methods: A systematic literature search (Medline, Pubmed and Embase) was conducted to identify all clinical
studies that investigated the association between cardiovascular disease and osteoporosis. Relevant studies were
screened for quality according to guidelines as proposed by the Dutch Cochrane Centre and evidence was
summarized.
Results: Seventy studies were included in this review. Due to a large heterogeneity in study population, design
and outcome measures a formal meta-analysis was not possible. Six of the highest ranked studies (mean n = 2,000)
showed that individuals with prevalent subclinical CV disease had higher risk for increased bone loss and fractures
during follow-up compared to persons without CV disease (range of reported risk: hazard ratio (HR) 1.5; odds ratio
(OR) 2.3 to 3.0). The largest study (n = 31,936) reported a more than four times higher risk in women and more
than six times higher risk in men. There is moderate evidence that individuals with low bone mass had higher CV
mortality rates and incident CV events than subjects with normal bone mass (risk rates 1.2 to 1.4). Although the
shared common pathophysiological mechanisms are not fully elucidated, the most important factors that might
explain this association appear to be, besides age, estrogen deficiency and inflammation.
Conclusions: The current evidence indicates that individuals with prevalent subclinical CV disease are at increased
risk for bone loss and subsequent fractures. Presently no firm conclusions can be drawn as to what extent low
bone mineral density might be associated with increased cardiovascular risk.
Introduction
Cardiovascular (CV) disease and osteoporosis are both
important causes of morbidity and mortality in aging
men and women. They share common risk factors, such
as increased age and inactivity, and are frequently found
in the same individuals, suggesting a possible relation-
ship. Results from epidemiological studies indicate an
association between CV disease and osteoporosis. Preva-
lent CV disease and subclinical atherosclerosis have
been found to be related to low bone mass and
increased fracture risk [1-4]. Similarly, low bone mineral
density (BMD) has been related to increased cardiovas-
cular risk [5-8]. This relationship is often regarded as a
result of aging; however, recent evidence suggests a
direct association, independent of age and traditional
cardiovascular risk factors and accumulating evidence
from experimental research indicates a shared pathogen-
esis. A variety of factors that influence bone metabolism
* Correspondence: mt.nurmohamed@planet.nl
2Department of Internal Medicine, VU Medical Centre, De Boelelaan 1117,
1081 NV Amsterdam, The Netherlands
Full list of author information is available at the end of the article
den Uyl et al. Arthritis Research & Therapy 2011, 13:R5
http://arthritis-research.com/content/13/1/R5
© 2011 den Uyl et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.are involved in the development of vascular disease, for
example, atherosclerosis and vascular calcification. Inter-
estingly, several bone-related proteins are implicated in
the calcification process resulting in mineral deposition
[9]. This is important as calcification of the arterial wall
may be a marker for CV disease and was shown to pre-
dict CV events [10]. Given the importance of identifying
a person at risk for CV events or fractures, evidence for
an association of CV disease with osteoporosis might
have implications for screening decisions in patients
with low bone mass and vice versa. This review aims to
summarize all the present clinical literature about the
association between CV disease and osteoporosis and to
describe common pathophysiological mechanisms. The
results of this review are grouped into two topics: clini-
cal results, discussing the relationship between 1) cardi-
ovascular disease and osteoporosis and 2) vice versa. In
addition, the possible pathophysiological links of CV dis-
ease and osteoporosis will be discussed.
Materials and methods
Search strategy
A systematic search (in Medline, Pubmed and Embase)
was conducted to identify all clinical studies from 1966
to January 2010 (last updated 8 June 2010) that investi-
gated the association between cardiovascular disease and
osteoporosis. The following search terms for cardiovas-
cular disease were used: cardiovascular diseases, cere-
brovascular diseases and peripheral vascular diseases.
These searches were each combined with an osteoporo-
sis search block and duplicates were removed. Searches
were limited to human studies in the English, Dutch
and German languages. The complete Medline search is
available in Additional file 1. In addition, references
from the retrieved articles were scanned for additional
relevant studies.
Selection criteria
Abstracts were screened by one reviewer (DdU) and
studies were included in the review if they fulfilled the
following inclusion criteria: epidemiological studies
(including prospective, cross-sectional, case-control, or
retrospective studies) reporting the association between
CV disease and osteoporosis in the general population
or in patients with prevalent CV disease or low bone
mass. Cardiovascular disease was defined as coronary
heart disease (CHD) (myocardial infarction, angina
pectoris, coronary insufficiency or ischemic heart dis-
ease), cerebrovascular disease (stroke, transient
ischemic attacks), peripheral arterial disease (PAD)
(lower extremity claudication, arterial thrombosis/
embolism, ankle brachial index (ABI) <0.90) or subcli-
nical atherosclerosis measured as intima media thick-
ness (IMT) or vascular calcification. In addition, bone
mass had to be assessed as bone mineral density or
bone quality, and osteoporosis was defined as low
bone mass (T-score ≤-2.5) or increased fracture risk
(vertebral and non-vertebral). Exclusion criteria were:
reviews, letters, case-reports, intervention studies
and biomechanical studies. Studies in patients with
co-morbidity other than osteoporosis or CV disease
were also excluded. Finally, investigations using risk
factors of CV disease or osteoporosis as outcome mea-
surements, such as hypertension, metabolic syndrome,
atrial fibrillation, bone markers, and calcium supple-
mentation were not included.
Assessment of study quality
The quality of each manuscript was systematically
assessed with a checklist for cohort studies as proposed
by the Dutch Cochrane Collaboration [11] (Additional
file 2). Quality assessment included a scoring of the fol-
lowing components: definition of study population, the
likelihood of bias, adequate blinding, the accuracy of
outcome measurements, duration of follow-up and
selective loss-to follow-up, the appropriateness of the
statistical analysis and the clinical relevance. All items
had the following answer options: yes/no/too little infor-
mation to answer the question. We considered incom-
plete information or data important criteria for study
quality. Therefore, if the answer could not be given
because the study provided too little information, a
negative score (for example, “no”) was given. Each “no”
was scored and an equal weight was given to each item.
A maximum of 10 points could be given. The scores of
each study are given in Tables 1 and 2.
Statistical analysis
A formal meta-analysis of the prospective studies inves-
tigating the association between bone mass and risk for
cardiovascular events and mortality was not possible
due to extended heterogeneity between studies with
respect to the study population and methods used.
Furthermore, the number of prospective studies that
were eligible for pooling was too small for analysis. For
this reason, narrative summaries are provided in the
results section and quantitatively presented in Tables 1
and 2. The heterogeneity between studies in terms of
study population and outcome measures is shown in
Tables 1 and 2. Moreover, cross-sectional studies are
shown in Table 3.
Results
Studies included
Our search strategy resulted in 2,886 references. The
search strategy resulted in 70 relevant articles, including
9 studies prospectively assessing the relationship
between CV disease and osteoporosis and 18 prospective
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Study Study population
(years follow-up)
Number of
cases (%
women)
Postmenopausal
women
CV
disease
excluded
Mean
age
Outcome CV disease Outcome bone mass Results # Quality
Sennerby,
2009 [13]
Population-based
(20)
31,936
(NA)
NA Yes 67.9
to
74.4
CV disease by National
patient registry, ICD 9
codes
Incident hip fracture by National
patient registry, ICD 9 codes
Women:
HR: 4.42 (95% CI 3.49 to 5.61)
Men:
HR: 6.65 (95% CI 4.82 to 9.19)
3
Szulc,
2008 [14]
Population-based
(10)
781
(0%)
No No 65 AC by X-spine Incident fracture by hospital records or
X-ray
OR: 2.54 to 3.04 (P < 0.005 to
0.001)
3
Naves,
2008 [4]
Population-based
(4)
624
(51%)
NA No 65 AC by X-spine BMD lumbar spine and femur by DXA
Incident fracture by hospital record or
X-ray
Change BMD spine in
progression AC vs no
progression AC:
-1.48% vs 1.43% (P <.0001)
Change BMD hip in
progression AC and no
progression AC:
-0.48% vs 0.23% (P = 0.315)
Incident fracture:
OR: 2.13 (95% CI 0.85 to 5.31)
3
Von
Muhlen,
2009 [15]
Population-based
(4)
1,332
(60%)
NA No 73.8 PAD by ABI BMD lumbar spine and hip by DXA
and incident fracture by X-ray
Women:
Change BMD in PAD vs no
PAD:
59.2% vs 43.5% (P < 0.05)
Incident non-vert fracture:
OR: 0.84 (95% CI 0.31 to 2.26)
Men :
Change BMD in PAD vs no
PAD :
43.5% vs 35.5% (P = 0.20)
Incident non-vert fracture:
OR: 1.52 (95% CI 0.30 to 7.45)
3
Collins,
2009 [2]
Population-based
(5.4)
4,302
(0%)
NA No 73.5 PAD by ABI BMD hip by DXA
Incident fractures by x-ray and hospital
records
Change BMD in PAD vs no
PAD:
-0.60% vs -0.32% (P < 0.001
PAD and non-vert fracture risk:
HR = 1.47 (95% CI 1.07 to 2.04)
3
Hak,
2000 [3]
Population-based
(9)
236
(100%)
No (100%) No 49 AC by X-spine MCA by radiogrammetry MCA in patients with AC
progression vs no AC
progression
-3.5 mm vs -2.0 mm (P < 0.01)
3
Samelson,
2007 [12]
Population-based
(21)
2,499
(58%)
No 61 AC by X-spine Incident hip fracture by hospital
records and death certificates
Women:
HR: 1.4 (0.8 to 2.3)
Men:
HR: 1.2 (0.2 to 5.7)
4
Bagger,
2006 [1]
Population-based
(7.5)
2,262
(100%)
Yes (100%) No 65 AC by X-spine BMD lumbar spine and hip and
incident fractures by hospital records
or X-ray
Change hip BMD AC score ≥3
vs <3:
-0.38% vs -0.25% (P < 0.001)
AC and hip fracture:
OR: 2.3 (95% CI 1.1 to 4.8)
AC and vert fracture:
OR: 1.2 (95% CI 1.0 to 1.5)
4
Schulz,
2004 [17]
Clinic-based
(8)
228
(100%)
Yes No 65.2 AC by CT-scan of spine BMD spine by CT-scan Change BMD AC vs no AC:
-5.3% vs -1.3% (P < 0.001)
6
#adjusted for confounders; NA, not available; AC, aortic calcification; BMD, bone mineral density; DXA, dual-energy x-ray absorptiometry; PAD, peripheral arterial disease; ABI, ankle brachial index; MCA, metacarpal cortical area.
d
e
n
U
y
l
e
t
a
l
.
A
r
t
h
r
i
t
i
s
R
e
s
e
a
r
c
h
&
T
h
e
r
a
p
y
2
0
1
1
,
1
3
:
R
5
h
t
t
p
:
/
/
a
r
t
h
r
i
t
i
s
-
r
e
s
e
a
r
c
h
.
c
o
m
/
c
o
n
t
e
n
t
/
1
3
/
1
/
R
5
P
a
g
e
3
o
f
1
9Table 2 Prospective studies investigating relationship low BMD and CV disease
Study Study
population
(years
follow-up)
Number
of cases
(%
women)
Postmenopausal
women
CV
disease
excluded
Mean
age
(years)
Race Outcome osteoporosis Outcome CV disease Results # Quality
(x nee)
Mussolino,
2007 [69]
Population-
based
(9)
5,272
(NA)
NA Yes 60.9 to
69.4
Caucasian (NA
%), black and
Mexican-
American
BMD proximal femur by DXA CV and stroke
mortality by death
certificates
Women:
BMD and CV mortality RR: 1.26
(95% CI 0.88 to 1.80)
BMD and stroke mortality: RR:
1.34 (95% CI 0.86 to 2.07)
Men:
BMD and CV mortality: RR:
1.05 (95% CI 0.79 to 1.39)
BMD and stroke mortality: RR;
0.73 (95% CI 0.43 to 1.23)
3
Farhat,
2007 [6]
Population-
based
(5.4)
2,310
(55%)
Yes Yes 73.5 Caucasian
(58%) and
black
BMD total hip, femoral neck and
trochanter by DXA
BMD spine by CT-scans
Incident CV disease by
hospital records and
death certificates
Women: BMD fem neck and
incident CV disease: HR: 1.24
(95% CI 1.02 to 1.52)
Men: BMD fem neck and
incident CV disease:
HR: 1.04 (95% CI 0.89 to 1.21)
3
Tamaki,
2009 [75]
Population-
based
(10)
609
(100%)
Yes (60%) No 55.9 Japanese BMD lumbar spine and total hip
by DXA
IMT values <10 YSM:
IMT OP vs normal bone mass:
1.55 vs 1.19 (P < 0.05)
≥YSM:
IMT OP vs normal bone mass:
1.53 vs 1.28 (P < 0.05)
3
Browner,
1991 [5]
Population-
based
(2.8)
9,704
(100%)
Yes No NA Caucasian
(99%) and
Asian
BMD distal radius, prox radius
and calcaneus by single photon
absorptiometry
Overall mortality and
CV mortality by death
certificates
BMD and risk overall mortality:
RR: 1.22 (95% CI 1.01 to 1.47)
BMD and stroke mortality: RR:
1.75 (95% CI 1.15 to 2.65)
BMD and CV mortality: RR:
1.17 (95% CI 0.92 to 1.51)
3
Trone,
2007 [68]
Population-
based
(7.6)
1,580
(60%)
Yes (NA %) No 71.9 Caucasian Prevalence vertebral fracture by
lateral spine radiographs
Overall mortality by
death certificates
Women: prevalent vertebral
fracture and overall mortality:
HR: 1.15 (95% CI 0.83 to 1.59)
Men: prevalent vertebral
fracture and overall mortality:
HR: 0.98 (95% CI 0.55 to 1.46)
3
Kado,
2000 [64]
Population-
based
(3.5)
6,018
(100%)
Yes No 76.5 Caucasian BMD total hip by DXA Overall and CV
mortality by death
certificates
BMD and overall mortality: RH:
1.3 (95% CI 1.1 to 1.4)
BMD and CV mortality: RH: 1.3
(95% CI 1.0 to 1.9)
4
Trivedi,
2001 [67]
Population-
based
(6.7)
1,002
(0%)
No women
included
No 69.7 NA BMD total hip by DXA Overall and CV
mortality by death
certificates
BMD and overall mortality: RR:
0.79 (95% CI 0.65 to 0.97)
BMD and CV mortality: RR:
0.72 (95% CI 0.56 to 0.93)
4
Tanko,
2005 [76]
Clinic-based
(4)
2,576
(100%)
Yes No 66.5 NA BMD lumbar spine and femoral
neck by DXA
Incidence CV events
self-reported and
confirmed by primary
documents
HR: 3.9 (95% CI 2.0 to 7.7) 4
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9Table 2 Prospective studies investigating relationship low BMD and CV disease (Continued)
Pinheiro,
2006 [66]
Population-
based
(5)
208
(100%)
Yes No 75.1 Caucasian BMD lumbar spine, femoral neck
and trochanter by DXA
Overall and CV
mortality by death
certificates
BMD and overall mortality: HR:
1.44 (95% CI 1.06 to 2.21)
BMD and CV mortality: HR:
1.28 (95% CI 1.08 to 2.26)
4
Johansson,
1998 [7]
Population-
based
(7)
1,468
(56%)
Yes No 74.0 Caucasian BMD calcaneus by DPA Overall mortality by
death certificates
Women: RR: 1.19 (95% CI 1.02
to 1.39)
Men: RR: 1.23 (95% CI 1.10 to
1.41)
4
Mussolino,
2003 [65]
Population-
based
(18.5)
3,402
(NA)
NA Yes NA Caucasian
(87%) and
black
BMD phalangeal by single
photon absorption
Stroke mortality by
death certificates
Women: RR: 1.01 (95% CI 0.86
to 1.19)
Men: RR: 1.13 (95% CI 0.93 to
1.38)
Blacks: RR : 0.93 (95% CI 0.72
to 1.21)
4
Samelson,
2004 [70]
Population-
based
(30)
2,059
(60%)
Yes (85,3-94%) Yes 60.2 NA Second MCA by radiogrammatry Incidence coronary
heart disease by
hospital records and
death certificates
Women: HR: 0.73 (95% CI 0.53
to 1.00)
Men: HR: 1.14 (95% CI 0.84 to
1.56)
4
Kiel, 2001
[77]
Population-
based
(25)
554
(66%)
NA No 54.4 NA Second MCA by radiogrammetry AC by radiograph of
the lumbar spine
Women: Sign association %
change in MCA and change
AC index (P = 0.01)
Men: No association % change
MCA and change AC index
(P = 0.50)
4
Browner,
1993 [62]
Population-
based
(1.98)
4,024
(100%)
Yes Yes NA Caucasian BMD distal radius and calcaneus
by single photon absorptiometry
Incident strokes by
hospital records and
death certificates
HR: 1.31 (95% CI 1.03 to 1.67) 5
Von der
Recke,
1999 [8]
Clinic-based
(17)
1,063
(100%)
Yes Yes 50 and
70
NA BMD distal forearm by single
photon absorptiometry with
125I
source
CV mortality by death
certificates, hospital
records and autopsy
reports
Early menopause: RR: 2.3 (95%
CI 1.0 to 5.3)
Late menopause: RR: 1.3 (95%
CI 0.9 to 1.8)
5
Silverman,
2004 [71]
Clinic-based
(3)
2,565
(100%)
Yes No 67 Caucasian
(95.8%)
Prevalence vertebral fracture by
lateral spine radiographs
Incident CV event self-
reported and
confirmed by primary
documents
CV event rate women with
prevalent vertebral fracture vs
no vertebral fracture: 15.1 vs
8.3 (P = 0.55)
5
Varosy,
2003 [73]
Clinic-based
(4.1)
2,763
(100%)
Yes Yes NA NA Prevalent and incident skeletal
fracture self-reported. Incident
fractures were confirmed by
radiological reports
Incident coronay event
by hospital records
HR: 0.75 (95% CI 0.57 to 0.98) 5
Gonzales-
Macias,
2009 [63]
Clinic-based
(3)
5,201
(100%)
Yes No 72.3 Caucasian eBMD calcaneus by QUS Overall and CV
mortality by medical
records
eBMD and overall mortality:
HR: 1.19 (95% CI 0.97 to 1.45)
eBMD and CV mortality: HR:
1.39 (95% CI 1.15 to 1.66)
6
#adjusted for age; AC, aortic calcification; BMD, bone mineral density; DPA, dual photon absorptiometry; DXA, dual-energy x-ray absorptiometry; IMT, intima media thickness; MCA, metacarpal relative cortical area;
NA, not available; QUS, quantitative ultrasonography; YSM, years since menopause.
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9Table 3 Cross-sectional studies investigating relationship CV disease and low BMD
Study Study
population
Number
of cases
%
women
Outcome bone mass Outcome CV disease Main results #
Frye,
1992 [35]
Population-
based
200 100% BMD lumbar spine and hip by
single photon absorptiometry
AC by x-ray Association AC and BMD lumbar spine:
b-2.213 (P < 0.05)
Association AC and BMD hip: b-0.661
(NS)
Barengolts,
1998 [32]
Clinic-
based
45 100% BMD lumbar spine and hip by
DXA
Coronary calcium
score by EBT
Correlation BDM hip and calcium score:
r-0.34 (P = 0.022)
Correlation BMD spine and calcium
score: r-0.28 (P = 0.056)
Jorgensen,
2001 [27]
Clinic-
based
63 52% BMD femoral neck by DXA Incident stroke Women:
OR: 6.6 (95% CI 1.8 to 24.8)
Men:
OR: 0.6 (95% CI 0.1 to 2.3)
Aoyagi,
2001 [40]
Population-
based
524 100% BMD distal and proximal radius,
calcaneus single photon
absorptiometry by sinlge photon
absorptiometry
AC by x-ray BMD distal radius and AC: OR: 1.1 (95%
CI 0.9 ro 1.3)
BMD calcaneus and AC: OR: 1.1 (0.9 to
1.3)
Van der Klift,
2002 [29]
Population-
based
5,268 57% BMD lumbar spine and hip by
DXA
PAD by ABI Women:
PAD and BMD hip: OR: 1.35 (95% CI
1.02 to 1.79)
Men:
PAD and BMD hip: OR: 0.89 (95% CI
0.64 to 1.23)
Tanko,
2003 [39]
Population-
based
963 100% BMD hip and lumbar spine by
DXA
AC by x-ray AC and BMD hip: b-0.10, 9 (P = 0.004)
Hirose,
2003 [56]
Clinic-
based
7,865 9% OSI calcaneus baPWV Women: b-0.11 (P < 0.01)
Men: b-0.07 (P < 0.01)
Pennisi,
2004 [50]
Clinic-
based
36 44% BMD total body, lumbar spine,
and hip by DXA and calcaneus
by QUS
IMT and presence of
plaque in carotid
artery
63% patients with BMD spine T <-1
93% patients with BMD hip T <-1
Jorgensen,
2004 [47]
Population-
based
5,296 52% BMD distal radius by single x-ray
absorptiometry
IMT and prevalent
plaque
BMD and IMT: NS
BMD and prevalent plaque: OR: 0.90
(95% CI 0.75 to 1.07)
BMD and echogenic plaque: OR: 0.51
(95% CI 0.31 to 0.83)
Montalcini,
2004 [49]
Clinic-
based
157 100% BMD calcaneus by QUS IMT BMD and IMT: NS
Magnus,
2005 [23]
Population-
based
5,050 36% BMD hip by DXA Self reported CV
events
Women:
OR: 1.22 (0.80 to 1.86)
Men:
OR: 1.39 (95% CI 1.03 to 1.87)
Bakhireva,
2005 [31]
Population-
based
366 51% BMD lumbar spine and hip by
DXA
CAC by CT scan Women:
BMD hip and CAC: OR: 0.69 (95% CI
0.51 to 0.93)
Men:
BMD hip and CAC: OR: 1.03 (0.75 to
1.41)
Wong,
2005 [30]
Population-
based
3,998 50% BMD lumbar spine and hip by
DXA
PAD by ABI Per SD increase in ABI sign associated
with hip BMD:
0.5 (95% CI 0.02 to 0.9)
Yamada,
2005 [53]
Clinic-
based
260 59% BMD lumbar spine by DXA and
OSI calcanues
IMT carotid artery and
femoral artery
BMD lumbar spine and FA-IMT: r-0.117
(P < 0.005)
Farhat,
2006 [34]
Population-
based
490 100% vBMD spine by CT scan AC and CAC by CT
scan
AC and BMD: OR: 1.68 (95% CI 1.06 to
2.68)
CAC and BMD: OR: 1.19 (95% CI 0.81 to
1.74)
Farhat,
2006 [19]
Population-
based
1,489 51% BMD hip by DXA
vBMD lumbar spine by QCT
Prevalent CV disease
self reported Prevalent
PAD by ABI
Women:
Prevalent CV disease and BMD hip: OR:
1.22 (95% CI 1.03 to 1.43)
PAD and BMD hip: NS Men:
Prevalent CV disease and BMD hip: NS
PAD and BMD hip: OR: 1.39 (95% CI
1.03 to 1.84)
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Page 6 of 19Table 3 Cross-sectional studies investigating relationship CV disease and low BMD (Continued)
Yamada,
2006 [54]
Population-
based
149 100% BMD lumbar spine by DXA and
vBMD calcaneus by QCT
IMT and PWV FA-IMT and BMD spine: b-0.067 (P <
0.05)
PWV and BMD spine: NS
Sumino,
2006 [60]
Clinic-
based
315 100% BMD lumbar spine by DXA baPWV Association baPWV and BMD: b-0.265 (P
= 0.002)
Sinnot,
2006 [43]
Clinic-
based
480 65% BMD lumbar spine by QCT Calcium score by CT-
scan
No correlation CAD and BMD in
women and men
Shaffer,
2007 [51]
Population-
based
870 61% BMD lumbar spine, hip and
distal radius by DXA
IMT Women >60 years:
IMT and BMD spine: b-73.0 (P < 0.001)
IMT and BMD hip: b-62.4 (P < 0.001)
Men >60 years:
IMT and BMD radius: b-27.0 (P < 0.001)
Sumino,
2007 [61]
Clinic-
based
85 100% BMD lumbar spine by DXA Brachial arterial
endothelial function
(FMD)
Correlation FMD and BMD: r .034 (P <
0.01)
Association FMD and BMD: b 0.40 (P <
0.01)
Hyder,
2007 [36]
Clinic-
based
365 64% BMD lumbar spine by CT-scan Atherosclerotic
calcium in carotid,
coronary and iliac
arteries by CT-scan
Women:
Calcium score aorta and BMD: OR: 3.14
(95% CI 1.55 to 6.38) Calcium score iliac
arteries and BMD: OR: 2.20 (95% CI 1.13
to 4.29)
Men:
Calcium score carotid and BMD: OR:
2.85 (95% CI 1.02 to 7.96)
Calcium score aorta and BMD: OR: 5.90
(95% CI 1.78 to 19.6)
Shen,
2007 [42]
Population-
based
682 56% BMD lumbar spine and hip by
DXA
CAC by CT scan CAC and BMD spine: -0.105 ± 0.132
(NS)
CAC and BMD hip: 0.022 ± 0.142 (NS)
Sioka,
2007 [24]
Clinic-
based
21 0% BMD lumbar spine and hip by
DXA
CAD by angiography BMD in severe CAD vs no CAD: 77.8%
vs 37.5%, P =?
Sumino,
2008 [52]
Clinic-
based
175 100% BMD lumbar spine by DXA IMT BMD and IMT b-0.313 (P = 0.001)
Kim,
2008 [48]
Clinic-
based
194 100% BMD lumbar spine and hip by
DXA
Prevalent vertebral fracture
IMT and prevalent
plaque
BMD and IMT: NS
BMD and plaque: NS
Vertebral fracture and plaque: OR: 2.8
(95% CI 1.17 to 7.12)
Frost,
2008 [45]
Clinic-
based
54 100% Lumbar spine and hip by DXA IMT and PWV BMD spine and IMT: r -.025 (P = 0.26)
BMD hip and IMT: r-0.17 (NS)
BMD and PWV: NS
Mangiafico,
2008 [57]
Clinic-
based
182 100% BMD lumbar spine and hip DXA PWA (AIx and PWV) BMD hip and AIx: b-5.46 (P < 0.0001)
BMD spine and Aix: b-3.29 (P < 0.0001)
Tekin,
2008 [25]
Clinic-
based
227 100% BMD lumbar spine by DXA Prevalence CAD CAD and low BMD: OR: 0.68 (95% CI
0.39 to 1.28)
Broussard,
2008 [18]
Population-
based
3,881 51% BMD total femur by DXA Framingham CHD risk
score by Framingham
CHD prediction
model
Women:
moderate CHD risk and low BMD: OR:
1.45 (95% CI 1.03 to 2.06)
high CHD risk and low BMD: OR: 1.73
(95% CI 1.12 to 2.66)
Men: NS
Chow,
2008 [41]
Population-
based
693 54% vBMD lumbar spine and hip by
QCT and vBMD distal radius by
HRpQCT
AC by CT-scan Women: NS
Men: NS
Hyder,
2009 [37]
NA 1,909 50% vBMD lumbar spine by CT scan CAC and AAC score Women:
vBMD and CAC (P-trend <0.002) vBMD
AND AAC (P-trend <0.004)
Men:
vBMD and CAC (P-trend <0.034)
vBMD and AAC (P-trend <0.001)
Hmamouchi,
2009 [46]
Clinic-
based
72 100% BMD lulmbar spine and hip by
DXA
IMT in carotid artery
and femoral artery
CA-IMT and BMD hip: r-0.330 (P < 0.05)
FA-IMT and BMD hip: NS
IMT and BMD lumbar spine: NS
Mikumo,
2009 [58]
Clinic-
based
143 100% BMD lumbar spine by DXA PWV BMD and PWV: r-99.78 (NS)
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the flow-chart of included and excluded studies.
Study results
The relationship between CV disease and osteoporosis
Cardiovascular disease and fracture risk Seven popu-
lation-based cohort studies assessed the relationship
between CV disease and fracture risk [1,2,4,12-15]
(Table 1). An increased risk of incident fractures was
observed in four studies with risk rates ranging from 1.2
to 6.7 [1,2,13,14].
The largest study included more than 30,000 twins
with a follow-up duration of 20 years [13]. In this study,
twins, without prevalent CV disease, were included at
the age of 50 years and followed up until a first hip frac-
ture, death or end of follow-up period. Twins were con-
sidered unexposed until the first CV event. An increased
hip fracture risk was found after all diagnoses of CV dis-
ease in both men (hazard ratio (HR) 6.65; 95% CI 4.82
to 9.19) and women (HR 4.42; 95% CI 3.49 to 5.61).
Furthermore, this study showed that CHD was asso-
ciated with an increased fracture risk (HR 2.32; 95% CI
1.91 to 2.84) as was cerebral vascular disease (HR 5.09
95% CI 4.18 to 6.20) [13]. This was confirmed in a large
population case-control study. This case-control study
was conducted using the Dutch PHARMO Record Link-
age System database. Patients (n =6 , 7 6 3 )w i t hah i p
fracture were compared with age- and sex-matched
patients without a hip fracture (n = 26,341), with the
objective to evaluate the association between stroke and
risk of hip fracture [16]. The prevalence of stroke was
3.3% in cases versus 1.5% in control patients. The risk
for a hip fracture was increased in patients who experi-
enced a stroke before the index date (OR 1.96; 95% CI
1.65 to 2.33).
Three studies looked at the association between PAD
and fracture risk. PAD was associated with increased
risk for non-vertebral fractures (HR 1.47; 95% CI 1.07
to 2.04) [2] and hip fractures (HR 3.20; 95% CI 2.28 to
4.50) [13]. In contrast, a smaller study in men and
women, with shorter follow-up time, did not find an
association between PAD and non-vertebral fracture
risk [15]. Time of follow-up might be an important fac-
tor explaining different results, for the risk of fractures
Table 3 Cross-sectional studies investigating relationship CV disease and low BMD (Continued)
Marcowitz,
2005 [20]
Clinic-
based
209 88% Lumbar spine, hip and distal
radius by DXA
CAD Osteoporosis: OR: 5.58 (95% CI 2.59 to
12.0) for CAD
Ness,
2006 [38]
Clinic-
based
1,000 100% Diagnosis osteoporosis or
osteopenia by electronic medical
records
AVD Prevalence AVD osteoporotis vs
osteopenia:
60% vs 35% (P < 0.001)
Prevalence AVD osteoporis vs normal
bone mass:
60% vs 22% (P < 0.001)
Gupta,
2006 [78]
Clinic-
based
101 100% BMD lumbar spine and total hip
by DXA
Prevalent CV disease Prevalent CV disease in low BMD vs
normal BMD:
61% vs 38% (P < 0.025)
Mangifico,
2006 [28]
Clinic-
based
345 100% BMD lumbar spine and femoral
neck by DXA
PAD by ABI PAD and BMD lumbar spine: OR: 1.01
(95% CI 0.97 to 1.05)
PAD and BMD hip: OR: 0.20 (95% CI
0.05 to 0.70)
Erbilen,
2007 [33]
Clinic-
based
74 0% BMD lumbar spine and hip by
DXA
CAD Association BMD and CAD:
OR: 5.4 (95% CI 1.66 to 17.49)
Sennerby,
2007 [21]
Clinic-
based
1,327 100% Incident hip fracture by X-ray
and hospital record
Prevalent CV disease
by questionnaire
OR: 2.38 (95% CI 1.92 to 2.94)
Varma,
2008 [22]
Clinic-
based
198 74% Lumbar spine and hip by DXA Obstructive CAD Prevalence CAD osteoporosis vs
osteopenia:
76% vs 68% (P < 0.01)
Prevalence CAD osteoporosis vs normal
bone mass:
76% vs 47% (P < 0.005)
Seo,
2009 [59]
Clinic-
based
253 100% BMD lumbar spine and hip by
DXA
baPWV Sign association BMD hip and baPWV:
Β-0.123 (P < 0.05)
Pouwels,
2009 [16]
Clinic-
based
6,763 73% Incident hip fracture Incident stroke by ICD
9 code
Risk hip fracture after stroke
Women: OR: 2.12 (95% CI 1.73 to 2.59)
Men: OR: 1.63 (95% CI 1.17 to 2.28)
#adjusted for confounders; BMD, bone mineral density; AC, aortic calcification; DXA, dual-energy x-ray absorptiometry; PAD, peripheral arterial disease; ABI, ankle
brachial index; OSI, osteosono assessment index; baPWV, brachial-ankle pulse wave velocity; IMT, intimal medial thickness; CAC, coronary artery calcium; QCT,
quantitative computerized tomography; PWV, pulse wave velocity; CAD, coronary artery disease; PWA, pulse wave analysis; AIx, augmentation index; CHD,
coronary hearth disease; AVD, atherosclerotic vascular disease.
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PAD [13].
Longitudinal analysis in healthy postmenopausal
women (n = 2,262) showed that aortic calcifications
(AC) represented a strong predictor for fragility frac-
tures: AC predicted a 2.3-fold increased risk for hip
fracture [1]. Not only women, but also men with
advanced AC have a two- to three-fold increased frac-
ture risk [14]. However, a large population-based study
with 21 years follow-up, found no evidence that severity
of vascular calcification, measured as AC, is associated
with an increased risk of incident hip fracture [12]. Con-
flicting results might be due to differences in population
and methodology. The incident fracture rates were
equal in comparison to the other studies.
Hence, although heterogeneity makes it difficult to
draw firm conclusions, there is evidence that subjects
with atherosclerotic disease are at an increased risk for
frailty fractures. There are insufficient data to draw con-
clusions about fracture risk in patients with prevalent
coronary or cerebral CV disease.
Cardiovascular disease and bone loss Longitudinal
data about CV disease and bone loss were available
from six studies [1-4,15,17]. All studies showed that pre-
valent CV disease was associated with an increased bone
loss during follow-up, independent of age and tradi-
tional risk factors. In addition, several cross-sectional
studies similarly reported that prevalent CV disease is
associated with low BMD [18-22]. In the next section
the results are presented per subcategory of CV disease.
The association of CHD and BMD was only addressed
in cross-sectional studies and all but one found an asso-
ciation with low BMD [20,22-25]. Several studies
reported increased bone loss after an incident stroke.
Particularly patients who are wheelchair-bound or have
paretic limbs as a result of the stroke have significant
bone loss within months after the stroke [26]. These
studies were not included in this review, for the under-
lying pathogenesis is obvious. One study looked at bone
d e n s i t yi m m e d i a t e l ya f t e rt h es t r o k ea n df o u n dt h a t
female stroke patients have lower BMD than controls
[27]. Since the BMD measurement was assessed within
Figure 1 Flow-chart of the systematic review.
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ble differences are not a result of immobilisation.
A large prospective study found that men with preva-
lent PAD had an increased rate of hip bone loss com-
pared with men without PAD (-0.6% vs -0.3%, P <
0.001) [2]. In another, smaller, study the association
between PAD and bone loss in women was weaker and
not observed in men [15]. In addition, a number of
cross-sectional studies showed that women and/or men
with PAD have decreased BMD [19,28-30].
Numerous reports have looked at the association
between subclinical atherosclerosis and osteoporosis.
M e na n dw o m e nw i t hp r o g r e ssion of AC have signifi-
cantly higher bone loss in the lumbar spine compared
with subjects without AC progression (-1.5% vs 1.4%)
[4]. This is in line with other studies where AC progres-
sion is associated with higher rates of bone loss in the
proximal femur and metacarpal bones [1,3]. Further-
more, several studies confirmed the prospective data
and showed that subjects with calcifications in the
aorta, coronary arteries, carotid arteries or femoral
arteries have significant lower BMD compared with
controls [31-39]. Only a few studies fail to find an asso-
ciation [40-43]. In recent years, many studies have
examined the association between atherosclerosis and
osteoporosis. An increased IMT has been associated
with severity of atherosclerosis and increased cardiovas-
cular risk and considered useful in identifying subjects
with increased risk [44]. An association between IMT
and BMD was studied intensively and most of the stu-
dies reported an association of increased IMT with low
bone density [45-54]. Endothelial dysfunction is consid-
ered to be an early phase of atherosclerosis and one
way to measure this is to focus on arterial compliance.
The endothelium plays an important role in determin-
ing vascular tone and dysfunction will result in
increased arterial stiffness [55]. In line with earlier dis-
cussed results, an increased arterial stiffness is asso-
ciated with low BMD [45,54,56-61].
Altogether, the results strongly suggest that subjects
with subclinical atherosclerosis and early CV disease are
at increased risk of bone loss. Again, there were insuffi-
cient data to reach conclusions about bone loss in
patients with prevalent coronary or cerebral CV disease.
The relationship between osteoporosis and CV disease
Eighteen studies, most of moderate quality, reporting
about the relationship between osteoporosis and CV dis-
ease were included. Results will be discussed per subca-
tegory of CV disease, when possible.
Low bone mineral density and cardiovascular mortal-
ity The association of osteoporosis with CV mortality
was studied in 10 prospective studies [5,7,8,62-68]
(Table 2). Low bone mass was inversely related with
CV mortality in seven studies [5,7,8,62-64,66,67].
Postmenopausal women with a low BMD had a 1.2- to
2.3-fold increased risk of dying from CV events, inde-
pendent of traditional CV risk factors [7,8,66]. Similar
results were found in elderly men [7,67]. Studies in
postmenopausal women with relative short follow-up
periods (around three years) showed no or minimally
significant elevated mortality rates [5,63,64]. Two large
population-based studies in elderly men and women did
not reveal a significant association between low bone
mass and CV mortality [65,69]. The most recent and
largest study determined the risk of CV mortality in
5,272 persons [69]. Women with low BMD had higher
risk for CV mortality; however, this did not reach signif-
icance (relative risk (RR) 1.26; 95% CI 0.88 to 1.80). No
association was found in men.
Focusing on the few studies that reported the results
per CV subcategory, women with low bone mass had no
or a small increased risk for mortality by coronary heart
disease (RR 1.17; 95% CI 0.92 to 1.51) and (relative
hazard 1.3; 95% CI 1.0 to 1.8), respectively [5,64] and
two out of three studies showed that men and women
with low BMD had a 1.3- to 1.7-fold increased risk for
stroke mortality [5,62,65].
Low bone mineral density and incident cardiovascu-
lar disease A total of six studies assessed the risk of
incident CV events in persons with osteoporosis
[6,62,70-73]. Most of them show a significant inverse
relationship between BMD and incident CV events in
women (HR 1.23 to 3.9) [6,39,62,70] but not in men
[6,70]. Two studies related the prevalence of vertebral
fractures with future CV events and were unable to find
any association [68,71]. Surprisingly, one study showed
that women with prevalent fractures and known CHD
had a reduced risk for CV events [73].
Few articles assessed incident CV events separated per
CV category. Three studies assessed the risk for CHD.
Two studies showed an association with increased risk
for CHD in postmenopausal women [72,73]. One study
could not find an association in elderly men and women
[70]. Cerebrovascular events were studied in two arti-
cles. Both found an increased risk for stroke in postme-
nopausal women with low BMD with hazard ratios of
1.31 and 4.1 [62,72].
There was a considerable heterogeneity in measure-
ment of osteoporosis. It is shown that the specificity and
sensitivity of the densitometry tests differs greatly, and
the site of measurement plays an important role in diag-
nosing osteoporosis as well [74]. Only six studies used
dual energy absorptiometry (DXA) measurements to
assess BMD [6,64,66,67,69,75,76], while in the other stu-
dies BMD was measured with older techniques such as
single photon absorptiometry, dual photon absorptiome-
try (DPA) or quantitative ultrasonography (QUS). Most
studies measured BMD of the hip and lumbar spine, but
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the phalangeals.
Low bone mineral density and subclinical athero-
sclerosis In addition to associations with CV events, low
BMD has also been shown to be associated with surro-
gate markers of CV disease, such as vascular calcifica-
tion. In women with the largest decrease in metacarpal
cortical area during a 25-year follow-up, the most severe
progression of aortic calcification was observed [77] and
women with a prevalent vertebral fracture had a higher
IMT measured 10 years later [75]. Moreover, results
from several cross-sectional studies confirmed that both
women and men with low bone mass, compared to sub-
jects with normal bone mass, have significantly more
subclinical atherosclerosis [20,28,31-34,37,38,45,48,
49,51,52,78,79], increased risk of peripheral arterial dis-
ease [28,29,34,54] and other surrogate end markers for
CV disease [57,60,61].
T a k e nt o g e t h e r ,t h e r ei ss o m ee v i d e n c et h a tp e r s o n s
with low BMD are at increased risk for CV events and
subsequent CV mortality. However, variations in study
design, for example, study population and outcome
measures, limits interpretation. Since only a few studies
assessed the CV outcome divided per CV subcategory,
no conclusions can be drawn concerning a relationship
between osteoporosis and specific categories of CV
disease.
Links between CV disease and osteoporosis
Common pathogenesis
CV disease is preceded by atherosclerosis, for example,
arterial disease. Atherosclerosis is a long-term process
in which deposits of cholesterol, cellular waste pro-
ducts and calcium accumulates in the arterial wall
causing it to thicken. Clinically, atherosclerosis is man-
ifested by coronary heart disease, cerebrovascular dis-
ease and peripheral arterial disease. Endothelial
dysfunction is the first step in the pathogenesis of
atherosclerosis and predicts future CV events [80]. Cal-
cification in the aorta and coronary arteries, for exam-
ple, vascular calcification, may be a surrogate marker
for atherosclerosis and increased CV risk [81]. In a
recent meta-analysis patients with calcifications were
found to have an increased risk for CV mortality and
events [10]. Presently, vascular calcification is regarded
as an active process, regulated by factors known to be
involved in the process of osteogenesis, such as bone
morphogenetic protein (BMP), alkaline phosphatase
(ALP), osteopontin (OPN) and matrix GLA protein
(MGP) [82-85] (Figure 2). Accumulating evidence sug-
gests that calcification is a consequence of active bone
formation by osteoblast-like cells [86]. Vascular
smooth muscle cells (VSMCs) are able to re-differenti-
ate towards osteoblast-like cells and a subpopulation,
that is, calcifying vascular cells (CVCs), were shown to
form nodules and mineralisation spontaneously [87].
In vitro, these osteoblastic cells produce hydroxyapa-
tite, a mineral important in bone formation [88]. In
the following paragraphs some of the bone-related fac-
tors that are involved in vascular calcification will be
discussed in more detail.
BMPs are members of the transforming growth factor-
b superfamily and important factors in the regulation of
osteoblast differentiation. BMP acts through upregula-
tion of transcription factors important in bone metabo-
lism, such as core binding factor-a1( C b f a1), also
known as runt-related transcription factor 2 (Runx2),
and msh homeobox 2 (Msx2). BMP appears to be an
important mediator in vascular calcification. An
increased expression of BMP2 and BMP4 is found in
atherosclerotic lesions in endothelial cells, foam cells
and VSMCs [88,89]. In vitro studies showed that several
factors that are known to induce CV disease, such
as oxidative stress, oxidized low-density lipoprotein
(ox-LDL) and tumor necrosis factor alpha (TNF-a),
are able to upregulate BMP expression in endothelial
cells [90,91].
MGP is a calcium-binding protein and requires vita-
min K to function. MGP is found to be expressed in
areas with arterial calcification [92] and may be an
important calcification inhibitor. MGP knock-out mice
developed extensive calcification in coronary arteries
[93]. Recently the mechanism by which MGP inhibits
calcification has become clear. In vitro,M G Ph a sb e e n
shown to inhibit calcification by binding to BMP2,
thereby blocking the induction of osteoblasts [94].
OPN is a glycoprotein that accumulates in the extra-
cellular matrix of bone tissue where it binds to hydro-
xyapatite and calcium. In bone, OPN is expressed by
(pre-) osteoblasts and osteoclasts and is also found to be
highly expressed in the atherosclerotic artery [89,92].
Whether it promotes or inhibits calcification in the
arterial wall is not completely clear [95]. While high
OPN serum levels are associated with vascular calcifica-
tion [96] and vitamin increases OPN and subsequent
calcification in bovine VSMC’s [97], OPN is also shown
to inhibit calcification by inhibiting de novo hydroxyapa-
tite production [98].
ALP is found on the surface of osteoblasts and is often
used as a marker for bone turnover. ALP is an enzyme
that catalyses the hydrolysis of phosphate esters. Hydro-
lysis of pyrophosphate, which is an inhibitor of hydro-
xyapatite formation, is especially needed to facilitate
normal mineralisation [99]. In vitro studies in VSMC’s
showed that the ALP expression is increased in response
to inflammatory markers, LDL and oxidative stress and
this increased expression was associated with increased
mineralisation [100-102].
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nuclear factor-kB (RANK), osteoprotegerin (OPG) and
RANK ligand (RANKL) provides more insight into bone
metabolism [103]. Most interestingly, there is increasing
evidence that OPG is a key regulator in the pathogenesis
of osteoporosis and vascular calcification. OPG produc-
tion by osteoblastic cells is regulated by a number of
factors, including BMP-2, inflammation, estrogen, vita-
min D and oxidative stress [104]. OPG is expressed in
various tissues, including the skeleton and vascular wall,
a n ds e r v e sa sas o l u b l ed e c oy for RANKL [105]. Inter-
estingly, OPG knock-out mice show, in addition to
early-onset osteoporosis, increased vascular calcification
[106]. In vitro studies have shown that OPG appears to
be important for endothelial cell survival [107] and may
inhibit active calcification [108]. Surprisingly, while
experimental studies showed that OPG might protect
against vascular calcification, OPG levels appear to be
elevated in patients with CV disease. Several, but not all,
clinical studies found a correlation of high OPG serum
levels and more severe CV disease [45,50,62,109-111].
Other pathways interacting with OPG might explain this
discrepant finding. Estrogen deficiency results in an
increased vascular OPG/RANKL ratio with subsequent
increased calcification in an animal model [112].
Furthermore, pro-inflammatory cytokines are shown to
elevate OPG levels in patients with CV disease [113].
Thus, while OPG appears to play a role in the patho-
genesis of atherosclerosis, the exact mechanism remains
to be elucidated.
Another important mechanism linking CV disease and
osteoporosis is Wnt signalling, a combination of the
genes Wg (wingless) and Int. Animal models showed the
important role of Wnt signalling in bone formation
Figure 2 Vascular calcification. Vascular calcification is an active process regulated by factors known to be involved in the process of
osteogenesis. Vascular smooth muscle cells are able to differentiate towards osteoblast-like cells, promoted by a variety of stimuli, including
BMP, RANKL, oxidative stress, inflammation and estrogen deficiency. These osteoblastic cells produce osteocalcin and ALP, important factors in
mineralisation.
# Excessive vitamin D promotes mineralisation. * It is not clear whether OPN promotes or inhibits calcification in the arterial wall,
in bone mineralisation it is a known mineralisation inhibitor. Abbreviations: ALP, alkaline phosphatase; BMP, bone morphogenetic protein; Cbfa1,
core binding factor-a1; MGP, matrix GLA protein; Msx2, msh homeobox 2; OPG, osteoprotegerin; OPN, osteopontin; ox-LDL, oxidized low density
lipoprotein; RANKL, receptor activator of nuclear factor-B ligand; VSMC, vascular smooth muscle cell; Wnt, combination of wingless and Int.
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lipoprotein receptor-related protein 6 (LRP6) and
b-catenin [114]. Wnt signalling is suggested to play an
important role in bone formation and bone adaptation
to mechanical loading [115,116]. Interestingly, TNF-a
[117], oxidative stress [118] and vitamin D [119]
are shown to promote vascular calcification through
the Wnt signalling pathway and this supports the
hypothesis that Wnt signalling is an interesting new
molecular mechanism that influences bone and vascular
metabolism.
Common risk factors
CV disease and osteoporosis are both common diseases
in elderly men and women. While the increased preva-
lence of both conditions is often attributed to aging,
most of the associations found in observational studies
remain significant after adjustment for age. Other
important traditional risk factors are also shared, such
as inactivity, smoking, estrogen deficiency and chronic
inflammation, explaining part of the link between CV
disease and osteoporosis [9].
Estrogen deficiency is considered an important risk
factor for osteoporosis [120] and some studies suggest
estrogen deficiency to be a cardiovascular risk factor
[121-123]. Estrogen regulates bone turnover and the CV
system directly and indirectly through the effects on the
immune system, antioxidant system and other risk fac-
tors. After menopause, estrogen levels decrease rapidly
resulting in an upregulated osteoclast formation and dif-
ferentiation, inducing high bone turnover and acceler-
ated bone loss [124]. Furthermore, following estrogen
withdrawal the production and secretion of the pro-
inflammatory cytokines interleukin-6 (IL-6), interleukin-
1 and TNF-a is increased [116,125].
Presently, inflammation is considered to play an
important role in the process of atherosclerosis
[126,127]. Both cellular and humoral pathways of the
immune response contribute to an important part in the
pathogenesis of atherosclerosis [128]. Markers of inflam-
mation, such as pro-inflammatory cytokines and C-reac-
tive protein (CRP), are involved in the development of
atherosclerosis and CRP predicts cardiovascular events
independently of other CV risk factors [129,130]. There
is accumulating evidence that inflammation influences
bone metabolism and is considered to be the most
important cause of postmenopausal osteoporosis. Pro-
inflammatory cytokines enhance bone resorption
directly through an induction of osteoclastogenesis or
through the OPG pathway [116,131].
Recent research has identified new common mediators
for vascular calcification and bone loss, such as hyperli-
pidemia, oxidative stress and vitamin D deficiency. An
abnormal lipid profile, that is, high levels of total choles-
terol, LDL and triglycerides and low levels of high-
density lipoprotein (HDL), is known to play a key role
in development of atherosclerosis and CV disease
[132,133]. Interestingly, HDL is able to regulate the cal-
cification of VSMCs [134]. HDL inhibited the sponta-
neous and cytokine induced osteogenic differentiation of
CVCs in vitro. The role of lipids in the regulation of
bone mass is more complicated. While experimental
studies showed that ox-LDL influences bone metabolism
[135], results in observational studies are contradictory
[1,136-138].
Oxidative stress is believed to increase with age and is
associated with hypertension and atherosclerosis [139].
Free radicals have important effects on osteoclast differ-
entiation and function [140] and oxidative stress mar-
kers are significantly associated with BMD [141]. In
vitro, minimally oxidized low-density lipoprotein (MM-
LDL) enhances the differentiation of VSMC’st o w a r d s
osteoblastic cells. Interestingly, antioxidants inhibited
these effects [100].
The prevalence of vitamin D deficiency is high
among elderly men and women [142] and associated
with osteoporosis and increased fracture risk [143].
Observational studies showed an inverse association of
vitamin D deficiency with hypertension and CV events,
suggesting a role for low vitamin D [144-148]. Pro-
posed mechanisms are effects on myocardial gene
expression, the renin-angiotensin axis or through sec-
ondary hyperparathyroidism. Important risk factors as
physical condition and immobility were rarely assessed.
Animal models and in vitro studies on the other hand,
demonstrated that toxic levels of vitamin D induce
vascular calcification [97,149]. Interestingly, osteopro-
tegerin has been shown to inhibit the vitamin-induced
calcifications in an animal model [150]. It has been
suggested that vitamin D has a biphasic relation with
vascular calcification and that both vitamin D defi-
ciency and vitamin D excess results in increased vascu-
lar calcification.
Genetic studies
In complex, multifactorial diseases genetic factors are
believed to play an important role in the pathogenesis in
addition to environmental influences. Identifying candi-
date genes offers opportunities to gain more insight into
possible shared pathogenesis and common risk factors
in CV disease and osteoporosis. Many candidate genes
have been examined, mainly genes coding for known
factors, such as cytokines, bone-associated factors and
receptors. The genes that might be involved in both dis-
eases will be discussed here.
Polymorphism in the IL-6 gene, a cytokine involved in
bone metabolism and CV disease, might be an interest-
ingly candidate gene. A G174C polymorphism in the pro-
moter region of the IL-6 gene was shown to be associated
with low bone mass in the radius in postmenopausal
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increased CV risk in men [152].
Vitamin D receptor polymorphisms have been asso-
ciated in many studies with bone density [153,154].
Although this could not be replicated in a large meta-
analysis, it did show that the Cdx2 polymorphism was
associated with risk for vertebral fractures [155]. In
addition, the BsmI polymorphism was associated with
IMT and myocardial infarction (MI) [156,157], strength-
ening the possible role of vitamin D in linking CV dis-
ease and osteoporosis.
One of the most interesting candidate genes to men-
tion is the OPG gene, located on chromosome 8 and
several single nucleotide polymorphisms (SNPs) are
identified in this gene. So far, studies were able to
associate different SNPs with either bone density or vas-
cular disease. SNPs A163G and T245G were associated
with osteoporotic fractures [158]. The linked poly-
morphisms T950C and C1181C within the promoter
region of the OPG gene were associated with an
increased risk for CAD in men [159]. In addition,
C1181C was also associated with first-ever intracerebral
haemorrhage [160]. Furthermore, another SNP in the
promoter region in the TATA box was related to vascu-
lar morphology and function [161].
A genetic defect in the Wnt signalling pathway was
recently discovered in a family with features of meta-
bolic syndrome and early onset coronary artery disease
[162]. This rare mutation in the LRP6 gene is associated
with dyslipidemia, hypertension and diabetes. This find-
ing supports further research for mutations in genes
involved in the Wnt signalling pathway.
Collagen type I is an important protein in the minera-
lisation matrix and connective tissue. Mutations in this
gene are associated with low BMD and fracture risk
[163]. Interestingly, besides low BMD, individuals with a
SNP in the COL1A gene (rs42524) had an increased pre-
valence of stroke and MI [164].
The calcium-sensing receptor (CASR) is a receptor
involved in the regulation of calcium homeostasis.
AS N Pi nt h eCARS gene (A986S) was associated with
higher serum calcium and increased prevalence of cor-
onary artery disease (CAD) and MI [165]. This SNP was
also associated with low BMD in premenopausal women
[166]. However, the role in postmenopausal osteoporosis
is not clear, since several studies showed no association
of this SNP with BMD or fracture risk in postmenopau-
sal women [167,168].
An interesting candidate gene to mention is the klotho
gene. Defects in the klotho gene have been shown to
result in arteriosclerosis and increased IMT in klotho
deficient mice [169]. A SNP in this gene (G395A)w a s
associated with CAD. Surprisingly, this same SNP was
associated with bone density [170] and was suggested to
be involved in the pathophysiology of bone loss. This
SNP in the promoter region resulted in impaired func-
tion of the gene. What makes this gene interesting is
that it might offer a new treatment approach, because
the abnormalities seen in klotho-deficient mice can be
reversed by restoring the klotho expression [171].
Finally, polymorphisms in the apolipoprotein E
(APOE) gene has been studied intensively. It has been
associated with hypertension, atherosclerotic disease and
CV disease [172-174]. Furthermore, APOE gene poly-
morphisms have been suggested to be associated with
low BMD and fracture risk. However, a recent meta-
analysis was unable to show a strong and consistent
association with BMD and fracture incidence [175].
Discussion
Our study is the first to systematically review the epide-
miological literature about the association between CV
disease and osteoporosis. An extensive literature search
yielded 27 prospective studies addressing this relation-
ship. Due to considerable heterogeneity in study design
and outcome measurements the results could not be
pooled. Focusing on the methodologically strongest stu-
dies (those with minimal selection bias and the appro-
priate assessments, that is, a methodological score of
more than 3), our review indicates that the prevalent
subclinical CV disease predicts future fractures and
bone loss [2-4,13-15] (Table 4).
Furthermore, there is some evidence that low
bone mass predicts CV mortality and CV events
[6,62,68,69,75].
Interestingly, several studies demonstrated shared risk
factors, supporting the existence of a direct association
between vascular calcification and bone biology.
Due to the substantial diversity of patients and study
methods, pooled analysis was not considered appropri-
ate. Although numerous efforts were made to investigate
the association between CV disease and osteoporosis, a
vast majority of studies used secondary outcome mea-
surements, while a limited number of studies used pri-
mary outcome measurements such as incident CV
events or osteoporosis. Furthermore, the population stu-
died varied with respect to age, sex, baseline risk for CV
events or fractures and ethnicity. Larger prospective stu-
dies in elderly persons, men and women, are needed to
answer this question. To reduce heterogeneity we
encourage that in new studies well-defined outcome
Table 4 Summary of findings in high quality prospective
studies
Association No association
CV disease and OP N =6 N =0
Bone mass and CV events N =3 N =2
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Page 14 of 19measures should be incorporated, such as incident CV
disease presented per subcategory of CV disease and
measurement of BMD by DXA-scans on regular interval
periods.
Conclusions
The current evidence indicates that individuals with pre-
valent (sub)clinical CV disease are at increased risk for
bone loss and subsequent fractures. Presently, no firm
conclusions can be drawn to which extent low BMD
might be associated with increased cardiovascular risk.
Age, estrogen deficiency and inflammation represent the
most important common risk factors and the discovery
of new pathways, for example, OGP/RANKL and Wnt
signalling, might provide interesting new therapeutic
options. Altogether our results suggest that bone density
screening could be recommended in patients with pre-
valent CV disease.
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